Linda Bosserman, MD, assistant clinical professor and staff physician, City of Hope, explained that quality measurements allow patients access to important information that can help them make decisions about their care.
At the end of the day, patients want to be able to know what their best treatments options are and how their own health can improve. Linda Bosserman, MD, assistant clinical professor and staff physician, City of Hope, explained that quality measurements allow patients access to this information because without measures of quality, clinicians and health plans cannot exactly reflect on what it is they are doing well on.
Dr Bosserman said that basing improvements off of clinical trial results is not the most accurate method of evaluating quality. When there are patients with comorbidities on multiple medications and of various ethnic backgrounds, the small, selected number of participating study members in clinical trials doesn’t represent the real-time population.
Without the feedback, tools and processes that quality metrics offer, there is no means of improvement. Dr Bosserman said that she and her team didn’t see improvement until those outcomes were understood.
“Once we started measuring, you keep learning and you keep improving your processes and you standardize more and you talk to patients and you engage them more to keep them healthy and to try to target the right treatment to the right patient,” Dr Bosserman said. “These measures are the beginning of the transformation of this [healthcare] system.”
In addition, a part of measuring quality is taking into consideration patient-reported outcomes. Dr Bosserman said that the idea of a patient coming in for their clinical visit and saying they don’t feel well simply doesn’t work anymore. The provider needs the appropriate information on hand to address all of the patient’s concerns.
“If we can integrate the patient reported outcomes into our decision-making and our clinic visit, whether it’s a phone call or however that visit goes, we can much better address patient symptoms and hopefully minimize them not getting sick between treatments,” Dr Bosserman said. “I don’t know if we know the best system yet, but maybe we could integrate something that really tracks those outcomes.”
While integrating patient-reported outcomes is still in its beginning stages, Dr Bosserman is hopeful that emerging tools will help clinicians in the future.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More